NO118935B - - Google Patents
Download PDFInfo
- Publication number
- NO118935B NO118935B NO153656A NO15365664A NO118935B NO 118935 B NO118935 B NO 118935B NO 153656 A NO153656 A NO 153656A NO 15365664 A NO15365664 A NO 15365664A NO 118935 B NO118935 B NO 118935B
- Authority
- NO
- Norway
- Prior art keywords
- phosphating
- phosphate
- phosphoric acid
- salt
- weak
- Prior art date
Links
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 claims description 10
- 229910000165 zinc phosphate Inorganic materials 0.000 claims description 10
- 239000010452 phosphate Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 238000003756 stirring Methods 0.000 description 12
- 239000000203 mixture Chemical group 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 239000011833 salt mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- DZHMRSPXDUUJER-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;dihydrogen phosphate Chemical compound NC(N)=O.OP(O)(O)=O DZHMRSPXDUUJER-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- LKCUKVWRIAZXDU-UHFFFAOYSA-L zinc;hydron;phosphate Chemical compound [Zn+2].OP([O-])([O-])=O LKCUKVWRIAZXDU-UHFFFAOYSA-L 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- XYFYNDJKSJAADQ-UHFFFAOYSA-L O.O.[Zn++].OP([O-])([O-])=O Chemical compound O.O.[Zn++].OP([O-])([O-])=O XYFYNDJKSJAADQ-UHFFFAOYSA-L 0.000 description 2
- -1 amine phosphate Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- NYZCHFJDJHGQDF-UHFFFAOYSA-K O.P(=O)([O-])([O-])[O-].[B+3] Chemical compound O.P(=O)([O-])([O-])[O-].[B+3] NYZCHFJDJHGQDF-UHFFFAOYSA-K 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YZYDPPZYDIRSJT-UHFFFAOYSA-K boron phosphate Chemical compound [B+3].[O-]P([O-])([O-])=O YZYDPPZYDIRSJT-UHFFFAOYSA-K 0.000 description 1
- 229910000149 boron phosphate Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- XNEOWYGUBMTFKT-UHFFFAOYSA-H trizinc;diphosphate;dihydrate Chemical compound O.O.[Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XNEOWYGUBMTFKT-UHFFFAOYSA-H 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- NDKWCCLKSWNDBG-UHFFFAOYSA-N zinc;dioxido(dioxo)chromium Chemical compound [Zn+2].[O-][Cr]([O-])(=O)=O NDKWCCLKSWNDBG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G10/00—Treatment rooms or enclosures for medical purposes
- A61G10/02—Treatment rooms or enclosures for medical purposes with artificial climate; with means to maintain a desired pressure, e.g. for germ-free rooms
- A61G10/023—Rooms for the treatment of patients at over- or under-pressure or at a variable pressure
- A61G10/026—Rooms for the treatment of patients at over- or under-pressure or at a variable pressure for hyperbaric oxygen therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G7/00—Beds specially adapted for nursing; Devices for lifting patients or disabled persons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T292/00—Closure fasteners
- Y10T292/20—Clamps
- Y10T292/205—Ring
- Y10T292/212—With expanding or contracting means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nursing (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Invalid Beds And Related Equipment (AREA)
- Catalysts (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Description
Fremgangsmåte til fremstilling av faste fosfateringsmidler. Process for the production of solid phosphating agents.
Norsk patent nr. 89625 vedrører en fremgangsmåte til fremstilling av fosfate-ringsoppløsninger hvor man til første-gangsfremstillingen og eventuelt til komplettering av oppløsningene anvender faste saltblandinger, som inneholder fosforsyre i form av et sådant salt av en svak base, f. eks. aminfosfat, eller av en svak syre, f. eks. borfosfat, hvis til saltdannelsen med fosforsyren anvendte kationer ved oppløsning avsaltet ikke i vesentlig grad for-skyver pH-verdien like overfor den i saltet inneholdte fri syre. Disse faste salter kan ved siden av det primære fosfat, spesielt tungmetallfosfat, dessuten inneholde akseleratorer og andre badkomponenter i fast form. Disse saltblandinger inneholder den til innstilling av fosfateringslikevekten nødvendige mengde fosforsyre i form av et salt av en svak base, f. eks. i form av et aminfosfat, fortrinsvis urinstoffosfat, eller av en svak syre, f. eks. borfosfatmonohy-drat. Norwegian patent no. 89625 relates to a method for the preparation of phosphating solutions where, for the initial preparation and possibly for supplementing the solutions, solid salt mixtures are used, which contain phosphoric acid in the form of such a salt of a weak base, e.g. amine phosphate, or of a weak acid, e.g. boron phosphate, if the cations used for salt formation with the phosphoric acid when dissolving the salt do not significantly shift the pH value to the same level as the free acid contained in the salt. In addition to the primary phosphate, especially heavy metal phosphate, these solid salts can also contain accelerators and other bath components in solid form. These salt mixtures contain the amount of phosphoric acid required for setting the phosphating equilibrium in the form of a salt of a weak base, e.g. in the form of an amine phosphate, preferably urea phosphate, or of a weak acid, e.g. boron phosphate monohydrate.
Den foreliggende oppfinnelse går ut på en fremgangmåte til fremstilling av fosfateringssalter som ved sin oppløsning gir den ved vedkommende temperatur herskende fosfateringslikevekt. The present invention is based on a process for the production of phosphating salts which, when dissolved, gives the phosphating equilibrium prevailing at the relevant temperature.
Dette oppnås eksempelvis derved at This is achieved, for example, by
oppløsninger som inneholder fosfateringssaltet i fosfateringslikevekt, ved hjelp av svake baser, særlig ammoniakkderivater, i den til den fri fosforsyre svarende mengde, bringes til krystallisasjon. solutions containing the phosphating salt in phosphating equilibrium, with the help of weak bases, especially ammonia derivatives, in the amount corresponding to the free phosphoric acid, are brought to crystallization.
Fremstillingen av disse faste fosfateringssalter skjer eksempelvis på den måte at man lar en fortrinsvis sterkt konsentrert oppløsning av primært sinkfosfat og fri fos- The production of these solid phosphating salts takes place, for example, in such a way that a preferably highly concentrated solution of primary zinc phosphate and free phosphate
forsyre krystallisere ved hjelp av en svak base til en saltblanding som inneholder det acid crystallize using a weak base into a salt mixture containing it
primære sinkfosfat og fosforsyren i form av vedkommende salt av denne svake base. primary zinc phosphate and the phosphoric acid in the form of the relevant salt of this weak base.
Som svak base anvender man fortrinsvis ammoniakkderivater, særlig urinstoff og Ammonia derivatives, especially urea and
dettes derivater, og man velger mengden its derivatives, and one chooses the quantity
av denne svake base slik at den er tilstrek-kelig til å binde den fri fosforsyre. Herunder avstemmer man fortrinsvis mengden av base slik at det på ett mol fri fosforsyre of this weak base so that it is sufficient to bind the free phosphoric acid. Here, the amount of base is preferably adjusted so that one mole of free phosphoric acid
kommer 1 til 2 mol base, særlig ammoniakkderivater. comes 1 to 2 moles of base, especially ammonia derivatives.
I den konsentrerte oppløsning av primært sinkfosfat og fosforsyre velger man forholdet mellom monosinkfosfat og fri fosforsyre slik at det tilsvarer fosfateringslikevekten ved den temperaturen ved hvilken de bad som skal fremstilles av saltet skal anvendes. Herunder kan man ved valg av den svake base ta med i beregningen at det på grunn av basens tilstedeværelse i den ferdige fosfateringsoppløsning inntrer en liten pH-forskyvning i forhold til en like-dan sammensatt oppløsning som ikke inne-holdt denne base. Man velger derfor fortrinsvis forholdet mellom sinkfosfat og fosforsyre i den konsentrerte oppløsning, fra hvilken det faste fosfateringssalt fremstilles, også i avhengighet av den svake bases styrke. In the concentrated solution of primary zinc phosphate and phosphoric acid, the ratio between monozinc phosphate and free phosphoric acid is chosen so that it corresponds to the phosphating equilibrium at the temperature at which the baths to be prepared from the salt are to be used. Below, when choosing the weak base, you can include in the calculation that due to the presence of the base in the finished phosphating solution, a small pH shift occurs in relation to a similarly composed solution that did not contain this base. The ratio between zinc phosphate and phosphoric acid in the concentrated solution, from which the solid phosphating salt is prepared, is therefore preferably chosen, also depending on the strength of the weak base.
De konsentrerte oppløsninger som de faste fosfateringssalter utvinnes av frem-stiller man fortrinsvis på den måte, at man går ut fra et sinksalt, eksempelvis sinkoksyd, sinkkromat eller tertiært sinkfosfat, og oppløser dette i konsentrert fosforsyre, fortrinsvis minst 75 pst.s syre. Etter avkjø-ling blir så krystallisering fremkalt ved å innføre den svake base i denne oppløsning. Det er herunder særlig fordelaktig hvis man før innføringen av den svake base gir oppløsningen en slik konsentrasjon, at det tilstedeværende vann nettopp er tilstrek-kelig til å la monosinkfosfat krystallisere som dihydrat. The concentrated solutions from which the solid phosphating salts are extracted are preferably prepared by starting from a zinc salt, for example zinc oxide, zinc chromate or tertiary zinc phosphate, and dissolving this in concentrated phosphoric acid, preferably at least 75% acid. After cooling, crystallization is then induced by introducing the weak base into this solution. It is particularly advantageous if, before the introduction of the weak base, the solution is given such a concentration that the water present is just sufficient to allow monozinc phosphate to crystallize as dihydrate.
Ved fremstillingen kan man føre sink-saltene, eksempelvis sinkoksyd, i fast form sammen med fosforsyren. Det er imidlertid også mulig å bringe en oppslemming av disse salter i vann sammen med fosforsyren, og deretter dampe bort det vann som forefinnes over den for monosinkfosfat-dihydratet nødvendigs mengde, før den svake base tilsettes. Ved tilsetningen av den svake base, særlig når urinstoff eller urinstoffderivater benyttes som svak base, må man passe på at temperaturen ikke sti-ger for høyt. Ved urinstoff bør temperaturen fortrinsvis holdes under 60° C, da det ellers inntrer spaltning. During production, the zinc salts, for example zinc oxide, can be introduced in solid form together with the phosphoric acid. However, it is also possible to bring a slurry of these salts in water together with the phosphoric acid, and then evaporate away the water that is present in excess of the amount required for the monozinc phosphate dihydrate, before the weak base is added. When adding the weak base, especially when urea or urea derivatives are used as a weak base, care must be taken that the temperature does not rise too high. In the case of urea, the temperature should preferably be kept below 60° C, otherwise decomposition will occur.
Valget av den svake base bestemmer samtidig også den mengde av samme som fortrinsvis blir å velge i forhold til den tilstedeværende fri syre. Velger man en særlig svak base, eksempelvis urinstoff, kan man tilsette så meget av den svake base at det dannes minst primære, eller også se-kundære fosfater eller blandinger av begge med den fri fosforsyre. Anvendelse av større mengder er uøkonomisk. Benytter man der-imot som svak base en noe sterkere base, eksempelvis guanidin eller guanylurinstoff, er det å anbefale bare å sette til så meget at det dannes monofosfat av den frie fosforsyre. I et hvert tilfelle er det tilstrekke-lig hvis det settes til base inntil monofos-fattrinet er nådd. I og for seg er det for fremstilling av fosfateringsoppløsningene mulig å anvende disse ferdige saltblandinger, i hvilke komponentene foreligger i konsentrasjonsforhold som tilsvarer like-vekten i det fosfateringsbad som skal fremstilles, og når oppløsningene skal fremstilles, tilsette dem de ønskede akseleratorer og andre bestanddeler. Man kan imidlertid også blande de i henhold til oppfinnelsen fremstilte fosfateringssalter med passende mengder av akseleratorer og ytterligere komponenter, og på denne måte forene alle de ønskede fosfateringsbads komponenter i en saltblanding, som anvendes for fremstilling av badet. The choice of the weak base also determines the quantity of the same which is preferably chosen in relation to the free acid present. If you choose a particularly weak base, for example urea, you can add so much of the weak base that at least primary or secondary phosphates or mixtures of both with the free phosphoric acid are formed. Application of larger quantities is uneconomical. If, on the other hand, a somewhat stronger base is used as a weak base, for example guanidine or guanyluronic substance, it is recommended to only add so much that monophosphate is formed from the free phosphoric acid. In each case, it is sufficient if it is added to the base until the monophos stage is reached. In and of itself, for the preparation of the phosphating solutions it is possible to use these ready-made salt mixtures, in which the components are present in concentration ratios that correspond to the equilibrium in the phosphating bath to be prepared, and when the solutions are to be prepared, add the desired accelerators and other ingredients to them. However, one can also mix the phosphating salts produced according to the invention with appropriate amounts of accelerators and additional components, and in this way combine all the desired phosphating bath components in a salt mixture, which is used for the preparation of the bath.
På tilsvarende måte er det mulig å fremstille saltblandinger som skal tjene til å komplettere fosfateringsoppløsningene, hvis det ikke velges fosfateringssystemer ved hvilke utgangsoppløsningene og kom-pletteringsoppløsningen har ens sammen-setning. Man kan da direkte kompietteré med disse kompletteringssalter, eller man kan oppløse dem først og benytte oppløs-ningene til kontinuerlig eller periodisk komplettering. In a similar way, it is possible to prepare salt mixtures that will serve to supplement the phosphating solutions, if phosphating systems are not chosen in which the starting solutions and the supplementing solution have the same composition. You can then directly compietre with these completion salts, or you can dissolve them first and use the solutions for continuous or periodic completion.
Også ved første gangs fremstilling av oppløsningene er det mulig først å opp-løse den faste saltblanding til en konsentrert oppløsning og så fortynne denne i badet til den ønskede konsentrasjon. Also when preparing the solutions for the first time, it is possible to first dissolve the solid salt mixture into a concentrated solution and then dilute this in the bath to the desired concentration.
Fremstillingen av de faste fosfateringssalter i henhold til oppfinnelsen skal be-skrives nærmere ved noen eksempler. The production of the solid phosphating salts according to the invention will be described in more detail with some examples.
Eksempel 1: Example 1:
For fremstilling av et kilo av et fast fosfateringssalt, som skal anvendes i en fosfateringsoppløsning ved 98° C, slemmer man opp 143 g sinkoksyd i 100 ml vann, og tilsetter langsomt 435 ml 86,5 pst.s fosforsyre under omrøring, og rører om inntil sinkoksyd et er oppløst. Oppløsningen opp-varmes langsomt under omrøring til 150° C og holdes ytterligere i 5—10 minutter ved denne temperatur under omrøring. Blandingen blir deretter avkjølt og under videre omrøring innfører man etterhvert 185 g urinstoff, hvorved temperaturen atter sti-ger og blandingen blir mere lettflytende. Det må dog passes på at temperaturen ikke går over 60° C. Under videre omrøring av-kjøler man til romtemperatur, hvorunder krystalliseringsprosessen understøttes ved omrøring og eventuelt inn-føring av kry-stalliseringskimer. Man får en tørr krystallblanding, hvis krystallstørrelse er av-hengig av omrøringsgraden. Utbyttet er 100 pst. Det dannede salt består av sink-monofosfatdihydrat og primært urinstoff-fosfat. For the production of one kilogram of a solid phosphating salt, which is to be used in a phosphating solution at 98° C, 143 g of zinc oxide is dissolved in 100 ml of water, and 435 ml of 86.5% phosphoric acid is slowly added while stirring, and stirred until zinc oxide is dissolved. The solution is slowly heated with stirring to 150° C and kept for a further 5-10 minutes at this temperature with stirring. The mixture is then cooled and, with further stirring, 185 g of urea is gradually introduced, whereby the temperature rises again and the mixture becomes more fluid. Care must be taken, however, that the temperature does not exceed 60° C. During further stirring, it is cooled to room temperature, during which the crystallization process is supported by stirring and possibly introducing crystallization germs. A dry crystal mixture is obtained, the crystal size of which depends on the degree of stirring. The yield is 100 per cent. The formed salt consists of zinc monophosphate dihydrate and primarily urea phosphate.
Til dette salt kan man blande 1040 g Zn(NO:t)2. 6H2O slik at det dannes en fer-dig fosfateringsblanding. 1040 g of Zn(NO:t)2 can be mixed with this salt. 6H2O so that a finished phosphating mixture is formed.
Eksempel 2: Example 2:
For fremstilling av et kilo fosfateringssalt som skal anvendes i en fosfatoppløs-ning ved 70° C ble 314 g tertiært sinkfosfat. 4H2O innført porsjonsvis i 296 ml 86,5 pst.s fosforsyre under omrøring. For å fjerne vannoverskudd ble det langsomt og under omrøring opphetet til 150° C og denne temperatur ble bibeholdt i 5—10 minutter un-. der omrøring. Etter avkjøling ble 207 g urinstoff innført under omrøring, hvorunder temperaturen ble holdt under 60° C. Deretter ble det avkjølt under omrøring, slik at det ble dannet en krystallblanding som besto av primært sinkfosfat-dihydrat og sekundært urinstoffosfat. For the production of one kilogram of phosphating salt to be used in a phosphate solution at 70° C, 314 g of tertiary zinc phosphate were used. 4H2O introduced portionwise into 296 ml of 86.5% phosphoric acid while stirring. To remove excess water, it was heated slowly and with stirring to 150° C and this temperature was maintained for 5-10 minutes. where stirring. After cooling, 207 g of urea was introduced with stirring, during which the temperature was kept below 60° C. It was then cooled with stirring, so that a crystal mixture consisting of primary zinc phosphate dihydrate and secondary urea phosphate was formed.
Til denne blanding kan man sette 156 g natriumklorat. 156 g of sodium chlorate can be added to this mixture.
Ved fremgangsmåten ifølge oppfinnelsen for fremstilling av faste fosfateringssalter kan man fremstille ikke bare salter for første gangs fremstilling og for komplettering av sinkfosfatbad, som i motset-ning til rent monosinkfosfat ikke er hygro-skopisk, men denne fremgangsmåte kan også benyttes for å få andre sjiktdannende fosfateringslikevekter i fast form, eksempelvis for fosfatering på manganfosfat-basis. Med særlig fordel anvendes imidlertid denne fremgangsmåte nettopp for fosfateringssalter på basis av sinkfosfat. With the method according to the invention for the production of solid phosphating salts, one can not only produce salts for the initial production and for supplementing zinc phosphate baths, which, in contrast to pure monozinc phosphate, are not hygroscopic, but this method can also be used to obtain other layer-forming phosphating equilibria in solid form, for example for phosphating on a manganese phosphate basis. With particular advantage, however, this method is used precisely for phosphating salts based on zinc phosphate.
Fosfateringssaltet kan man også fremstille under anvendelse av en svak syre, f. eks. borsyre. Også da går man ut fra en fosfatlikevektsoppløsning av et lagdannen-de fosfat, tilsetter denne en med den fri fosforsyre omtrent ekvivalent mengde borsyre, og bringer fosfateringssaltet til å krystallisere. The phosphating salt can also be prepared using a weak acid, e.g. boric acid. In that case, too, one starts from a phosphate equilibrium solution of a layer-forming phosphate, adds to this an approximately equivalent amount of boric acid with the free phosphoric acid, and brings the phosphating salt to crystallise.
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2411463A GB1022831A (en) | 1963-06-17 | 1963-06-17 | Improvements in or relating to hospital beds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO118935B true NO118935B (en) | 1970-03-02 |
Family
ID=10206598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO153656A NO118935B (en) | 1963-06-17 | 1964-06-15 |
Country Status (12)
Country | Link |
---|---|
US (1) | US3345985A (en) |
AT (1) | AT251187B (en) |
BE (1) | BE649407A (en) |
CH (1) | CH403162A (en) |
DE (2) | DE1791226B1 (en) |
DK (2) | DK116235B (en) |
ES (1) | ES300997A1 (en) |
FR (1) | FR1398618A (en) |
GB (1) | GB1022831A (en) |
NL (1) | NL6406877A (en) |
NO (1) | NO118935B (en) |
SE (1) | SE305511B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3858570A (en) * | 1972-06-12 | 1975-01-07 | Puritan Bennett Corp | Comprehensive infant care system |
US3851644A (en) * | 1973-01-12 | 1974-12-03 | Picker Corp | Method and apparatus for rapidly immobilizing a patient |
US4003371A (en) * | 1975-02-13 | 1977-01-18 | Fischer Boguslav | Low pressure hyperbaric chamber |
FR2330358A1 (en) * | 1975-11-07 | 1977-06-03 | Champeau Andre | ACOUSTICALLY INSULATED BED |
US4017917A (en) * | 1976-03-03 | 1977-04-19 | John R. Puckett | Cover |
US4236513A (en) * | 1979-04-18 | 1980-12-02 | Lopiano Rocco W | Pulsed oxygen chamber |
US4727870A (en) * | 1986-06-10 | 1988-03-01 | Hyperbaric Systems, Inc. | Hyperbaric chamber |
US6062215A (en) * | 1997-07-22 | 2000-05-16 | Kinetic Concepts, Inc. | Hyperbaric oxygen patient treatment system |
US20040177447A1 (en) * | 2003-03-10 | 2004-09-16 | Love Tommy L. | System for isolating a patient from a surrounding environment |
US20050045177A1 (en) * | 2003-08-29 | 2005-03-03 | Jeff Lacour | Method and system for treating sleeping disorders |
DE102008008997B4 (en) * | 2007-02-13 | 2016-01-14 | Kurt Oswald | Device for adjusting the air pressure above the lying surface of a bed |
GB201520065D0 (en) | 2015-11-13 | 2015-12-30 | Univ Oslo Hf | Patient isolator |
USD829884S1 (en) | 2015-11-16 | 2018-10-02 | Epiguard As | Patient isolator |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1449940A (en) * | 1919-08-15 | 1923-03-27 | Pressed Steel Tank Company | Removable head for metal containers |
GB404314A (en) * | 1931-07-08 | 1934-01-08 | Daniel Laguerre | Improvements in shelters |
US2240819A (en) * | 1934-02-10 | 1941-05-06 | Banneitz Hugo | Apparatus for medical treatment |
CH183332A (en) * | 1934-02-10 | 1936-03-31 | Abdalla Dr Med Waly | Enclosed storage facility primarily for people with lung disease. |
US2195744A (en) * | 1939-12-26 | 1940-04-02 | John H Emerson | Artificial respirator |
US2543426A (en) * | 1947-10-11 | 1951-02-27 | Ferdinand H Terhaar | Respirator |
DE821530C (en) * | 1948-10-02 | 1951-11-19 | Bernh Draeger | Device for artificial breathing |
GB683072A (en) * | 1949-11-16 | 1952-11-19 | Essex Aero Ltd | Improvements in hospital beds |
US2700384A (en) * | 1952-02-01 | 1955-01-25 | Harry S Ivory | Treatment chamber apparatus |
GB739856A (en) * | 1954-03-24 | 1955-11-02 | Laycock Eng Ltd | Improvements in plug-in pipe connections |
US2801428A (en) * | 1954-05-07 | 1957-08-06 | Ralph W Streeter | Bed |
FR1136521A (en) * | 1955-11-16 | 1957-05-15 | Le Materiel Medical Et Sanitai | Oxygen therapy device |
GB907524A (en) * | 1960-07-29 | 1962-10-03 | Vickers Res Ltd | Improvements in or relating to apparatus for treating patients under above atmospheric pressure |
-
1963
- 1963-06-17 GB GB2411463A patent/GB1022831A/en not_active Expired
-
1964
- 1964-06-10 US US37398464 patent/US3345985A/en not_active Expired - Lifetime
- 1964-06-13 ES ES0300997A patent/ES300997A1/en not_active Expired
- 1964-06-15 DE DE19641791226D patent/DE1791226B1/en active Pending
- 1964-06-15 NO NO153656A patent/NO118935B/no unknown
- 1964-06-15 FR FR978303A patent/FR1398618A/en not_active Expired
- 1964-06-15 DE DE19641491854D patent/DE1491854B1/en active Pending
- 1964-06-16 SE SE734464A patent/SE305511B/xx unknown
- 1964-06-16 AT AT514664A patent/AT251187B/en active
- 1964-06-17 CH CH786864A patent/CH403162A/en unknown
- 1964-06-17 BE BE649407A patent/BE649407A/xx unknown
- 1964-06-17 NL NL6406877A patent/NL6406877A/xx unknown
- 1964-06-17 DK DK304264A patent/DK116235B/en unknown
-
1966
- 1966-10-20 DK DK543766A patent/DK114646B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BE649407A (en) | 1964-10-16 |
US3345985A (en) | 1967-10-10 |
NL6406877A (en) | 1964-12-18 |
FR1398618A (en) | 1965-05-07 |
DK114646B (en) | 1969-07-21 |
DE1791226B1 (en) | 1970-10-15 |
ES300997A1 (en) | 1964-12-01 |
AT251187B (en) | 1966-12-27 |
DK116235B (en) | 1969-12-22 |
CH403162A (en) | 1965-11-30 |
SE305511B (en) | 1968-10-28 |
GB1022831A (en) | 1966-03-16 |
DE1491854B1 (en) | 1970-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US2407645A (en) | Aliphatic polycarboxylic amino acids and process of making them | |
NO118935B (en) | ||
US3290140A (en) | Method of mixing and storing solutions comprising ammonium phosphate | |
GB968305A (en) | Process for the preparation of metal ammonium phosphates | |
US4234332A (en) | Aqueous fertilizer solutions containing dicyandiamide | |
US3620708A (en) | Liquid fertilizers including soluble zinc from zinc oxide | |
US3022154A (en) | Concentrated liquid fertilizers from superphosphoric acid and potassium hydroxide | |
US2114280A (en) | Making guanidine salts | |
US2692281A (en) | Preparation of hydrazodicarbonamide | |
US3463817A (en) | Process for producing amine oxides | |
US3009949A (en) | Production of guanidine salts | |
US1889863A (en) | Preparation of double salts of calcium nitrate | |
US1859835A (en) | Process for the manufacture of microcosmic salt and other fertilizing material | |
US2285843A (en) | Nitrogen generating chemicals | |
US3547613A (en) | Liquid fertilizers | |
US2036701A (en) | Production of mixed fertilizer | |
GB620030A (en) | Preparation of guanidine salts | |
GB2076795A (en) | Aqueous fertiliser solutions | |
US1840229A (en) | Double salts | |
US3050539A (en) | Preparation of ferric chelates of alkylene amino acid compounds | |
US3130039A (en) | High analysis complex fertilizer preparation | |
US1844862A (en) | Method of producing hydrated metal nitrates | |
US2624761A (en) | Dicarbamylguanidine salts | |
US3041160A (en) | Stabilized plant nutrient composition | |
US2237826A (en) | Fertilizer composition |